reports
Melinta Therapeutics Announces Appointment of Christine Ann Miller as ...
Melinta Therapeutics Announces Appointment of Christine Ann Miller as President and Chief Executive Officer MORRISTOWN, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that its Board of Directors has appointed Christine Ann Miller as President and Chief Executive Officer and member of the board, effective August 3, 2020. In April of this year, Melinta became privately owned by affiliates of healthcare investment firm Deerfield Management Compan...
- GlobalData Department
Cempra Inc (CEMP) - Pharmaceuticals & Healthcare - Deals and Alliances...
Summary Cempra Inc (Cempra), formerly Cempra Holdings LLC is a pharmaceutical company that develops antibacterials to the critical medical needs. The company offers products which include solithromycin and fusidic acid. It offers solithromycin, an oral and intravenous fluoroketolide. Cempra offers fusidic acid which is active against gram-positive organisms including MRSA. The company offers macrolides which are antimicrobial drugs that are active against aerobic and anaerobic gram-positive coc...
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Cempra, ...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Cempra, Inc. (NASDAQ:CEMP) between October 22, 2015 and November 1, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Middle District of North Carolina. To get more information go to: http://www.zlk.com/pslra/cempra-inc or contact Joseph E. Levi, Esq. either via email at jlev...
GPM Reminds Investors of the January 3 Deadline in the Class Action La...
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the January 3, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Cempra, Inc. (“Cempra” or the “Company”) (NASDAQ: CEMP) securities between May 1, 2016 and November 1, 2016, inclusive (the “Class Period”). Cempra investors have until January 3, 2017 to file a lead plaintiff motion. The Complaint filed in this lawsuit alleges that throughout the Class Period, Defendant...
CEMP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Shareh...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Middle District of North Carolina on behalf of investors who purchased Cempra, Inc. (NASDAQ:CEMP) securities between October 22, 2015 and November 1, 2016. Click here to learn about the case: http://www.wongesq.com/pslra/cempra. There is no cost or obligation to you. According to the complaint, during the Class Period, Cempra made false and/or misleading statements and/or failed to d...
CEMP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Shareh...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Middle District of North Carolina on behalf of investors who purchased Cempra, Inc. (NASDAQ:CEMP) securities between October 22, 2015 and November 1, 2016. Click here to learn about the case: http://www.wongesq.com/pslra/cempra. There is no cost or obligation to you. According to the complaint, during the Class Period, Cempra made false and/or misleading statements and/or failed to d...
CEMP LOSS NOTICE: Rosen Law Firm Reminds Cempra, Inc. Investors of Imp...
NEW YORK--(BUSINESS WIRE)-- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Cempra, Inc. securities (NASDAQ:CEMP) from May 1, 2016 through November 1, 2016, both dates inclusive (the “Class Period”) of the important January 3, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Cempra investors under the federal securities laws. To join the Cempra class action, go to http://www.rosenlegal.com/cases-985.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free ...
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadli...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina on behalf of purchasers of Cempra, Inc. (Nasdaq: CEMP) (“Cempra” or the “Company”) securities during the period between October 22, 2015 and November 1, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until January 3, 2017 to se...
SHAREHOLDER ALERT: Securities Class Action Lawsuit Against Cempra Anno...
ATLANTA--(BUSINESS WIRE)-- Holzer & Holzer, LLC announces that a securities class action lawsuit has been filed against Cempra, Inc. (“Cempra” or the “Company”) (NASDAQ: CEMP) on behalf of investors who purchased its common stock between May 1, 2016 and November 1, 2016. The firm is investigating whether shareholders who purchased CEMP between October 22, 2015 and April 30, 2016 should also be included in the case. The lawsuit alleges Cempra omitted material facts when discussing its lead product candidate, solithromycin. On ...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Acti...
NEW YORK--(BUSINESS WIRE)-- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Cempra, Inc. securities (NASDAQ:CEMP) from May 1, 2016 through November 1, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Cempra investors under the federal securities laws. To join the Cempra class action, go to http://www.rosenlegal.com/cases-985.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email ...
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Act...
LOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Cempra, Inc. (“Cempra” or the “Company”) (Nasdaq: CEMP) concerning possible violations of federal securities laws between May 1, 2016 and November 1, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the January 3, 2017 lead plaintiff motion deadline. To participate in this class action lawsuit, click her...
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Cl...
IRVINE, Calif.--(BUSINESS WIRE)-- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Cempra, Inc. (“Cempra” or the “Company”) (Nasdaq: CEMP). Investors who purchased or otherwise acquired shares between May 1, 2016 and November 1, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm by the January 3, 2017 lead plaintiff motion deadline. If you purchased shares of Cempra during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman A...
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class ...
LOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Cempra, Inc. (“Cempra” or the “Company”) (Nasdaq: CEMP) concerning possible violations of federal securities laws between May 1, 2016 and November 1, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the January 3, 2017 lead plaintiff motion deadline. To participate in this class action lawsuit, click her...
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation ...
LOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Cempra, Inc. (“Cempra” or the “Company”) (Nasdaq: CEMP) concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at [email protected]. The investigation focuses on the November 2, 2016 announcement by the U.S. Food and Drug Administration, which posted a pr...
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Cempra, ...
LOS ANGELES--(BUSINESS WIRE)-- Goldberg Law PC announces that it is investigating Cempra, Inc. (“Cempra” or the “Company”) (Nasdaq: CEMP) concerning possible violations of federal securities laws. If you purchased or otherwise acquired Cempra shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You ...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of...
NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky announces it has commenced an investigation of Cempra, Inc. (“Cempra” or the “Company”) (NASDAQ: CEMP) concerning possible violations of federal securities laws by certain officers and directors. On November 2, 2016, the U.S. Food and Drug Administration posted a preliminary review on its website of Cempra’s drug, solithromycin, highlighting a significant safety signal for hepatotoxicity. Upon this news, shares of Cempra fell over 60% during intraday trading. To obtain additional i...
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigat...
IRVINE, Calif.--(BUSINESS WIRE)-- Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Cempra, Inc. (“Cempra” or the “Company”) (Nasdaq: CEMP) concerning possible violations of federal securities laws. If you purchased shares of Cempra and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected]. The investigation focuses on whether Cempra and certain...
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into Cempra...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into Cempra Inc. (“Cempra” or the “Company”) (NASDAQ: CEMP). The firm’s investigation is focusing on whether the Company and/or its officers and directors violated state or federal securities law. On November 2, 2016, the U.S. Food and Drug Administration posted a preliminary review on its website of Cempra’s drug, solithromycin, to treat community-acquired bacterial pneumonia highli...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.